GAIN THERAPEUTICS, INC Increase (Decrease) in Prepaid Expense and Other Assets
GAIN THERAPEUTICS, INC (GANX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $493.32 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $215.11K, a 47.34% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $278.21K, a 67.06% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$304.43K.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$866.39K, a 3920.25% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for fiscal 2025 was $82.12K, a 76.97% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for fiscal 2024 was $356.65K.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$54.38K, a 147.70% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC increase (decrease) in prepaid expense and other assets for fiscal 2022 was $114.00K, a 78.67% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $215.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $493.32K 10-Q · filed 2026-08-11 | $188.90K derived: sum of 3 quarters · filed 2026-08-11 | -$677.50K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $278.21K 10-Q · filed 2026-05-11 | -$26.21K derived: sum of 2 quarters · filed 2026-05-11 | -$892.61K derived: sum of 3 quarters · filed 2026-05-11 | -$484.15K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$304.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.17M derived: sum of 2 quarters · filed 2026-03-26 | -$762.37K derived: sum of 3 quarters · filed 2026-08-11 | $82.12K 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | -$866.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$457.94K derived: sum of 2 quarters · filed 2026-08-11 | $386.55K 10-Q · filed 2025-11-12 | $24.25K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $408.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.25M 10-Q · filed 2026-08-11 | $890.64K derived: sum of 3 quarters · filed 2026-08-11 | $913.32K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $844.48K 10-Q · filed 2026-05-11 | $482.19K derived: sum of 2 quarters · filed 2026-05-11 | $504.87K derived: sum of 3 quarters · filed 2026-05-11 | $905.69K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$362.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$339.62K derived: sum of 2 quarters · filed 2026-03-26 | $61.20K derived: sum of 3 quarters · filed 2026-03-26 | $356.65K 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $22.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $423.50K derived: sum of 2 quarters · filed 2025-11-12 | $718.95K 10-Q · filed 2025-11-12 | $741.10K 10-Q · filed 2024-11-14 | $689.59K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $400.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $696.27K 10-Q · filed 2025-08-12 | $701.77K 10-Q · filed 2024-08-08 | $666.91K derived: sum of 3 quarters · filed 2025-08-12 | $485.99K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $295.45K 10-Q · filed 2025-05-14 | $298.47K 10-Q · filed 2024-05-14 | $266.09K derived: sum of 2 quarters · filed 2025-05-14 | $85.17K derived: sum of 3 quarters · filed 2025-05-14 | -$308.57K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$29.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$210.28K derived: sum of 2 quarters · filed 2025-03-27 | -$604.01K derived: sum of 3 quarters · filed 2025-03-27 | -$54.38K 10-K · filed 2025-03-27 | -$184.45K 10-K · filed 2024-03-26 | |||
| 2023-09-30 | -$180.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$574.65K derived: sum of 2 quarters · filed 2024-11-14 | -$25.02K 10-Q · filed 2024-11-14 | -$32.07K 10-Q · filed 2023-11-14 | -$296.58K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$393.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $155.90K 10-Q · filed 2024-08-08 | $151.21K 10-Q · filed 2023-08-10 | -$115.67K derived: sum of 3 quarters · filed 2024-08-08 | -$598.39K derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $549.63K 10-Q · filed 2024-05-14 | $547.30K 10-Q · filed 2023-05-12 | $278.07K derived: sum of 2 quarters · filed 2024-05-14 | -$204.65K derived: sum of 3 quarters · filed 2024-05-14 | -$552.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$271.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$754.29K derived: sum of 2 quarters · filed 2024-03-26 | -$1.10M derived: sum of 3 quarters · filed 2024-03-26 | $114.00K 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | -$482.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$830.07K derived: sum of 2 quarters · filed 2023-11-14 | $385.57K 10-Q · filed 2023-11-14 | $972.35K derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$347.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $868.29K 10-Q · filed 2023-08-10 | $1.46M derived: sum of 3 quarters · filed 2023-08-10 | $851.35K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.22M 10-Q · filed 2023-05-12 | $1.21M 10-Q · filed 2022-05-16 | $1.80M derived: sum of 2 quarters · filed 2023-05-12 | $1.20M derived: sum of 3 quarters · filed 2023-05-12 | $1.23M derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $586.78K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$16.94K derived: sum of 2 quarters · filed 2023-03-23 | $12.69K derived: sum of 3 quarters · filed 2023-03-23 | $534.50K 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | -$603.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$574.10K derived: sum of 2 quarters · filed 2022-11-10 | -$52.28K 10-Q · filed 2022-11-10 | $17.13K derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $29.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $551.44K 10-Q · filed 2022-08-08 | $620.86K derived: sum of 3 quarters · filed 2022-08-08 | $736.23K derived: sum of 4 quarters · filed 2022-08-08 | ||||
| 2021-03-31 | $521.81K 10-Q · filed 2022-05-16 | $591.23K derived: sum of 2 quarters · filed 2022-05-16 | $706.60K derived: sum of 3 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $69.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $184.79K derived: sum of 2 quarters · filed 2022-03-25 | $117.70K 10-K · filed 2022-03-25 | |||||
| 2020-09-30 | $115.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $48.29K 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | -$67.08K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |